STRATA Skin Sciences, Inc. 8-K

What Happened
STRATA Skin Sciences, Inc. (SSKN) announced that Nasdaq will suspend trading in its common stock and remove the company from listing after SSKN failed to meet Nasdaq’s $2,500,000 stockholders’ equity requirement. Nasdaq accepted the company’s compliance plan but gave an extension only until February 16, 2026. After engaging two investment banks, confidentially filing an S-1, and holding numerous investor meetings, the company was unable to raise sufficient capital and informed Nasdaq on February 9, 2026 that it could not meet the extension. Nasdaq notified the company on February 10, 2026 that trading would be suspended at the opening of business on February 19, 2026 unless appealed; the company does not intend to appeal. SSKN expects to file a Form 25 to deregister under Section 12(b) on or about February 19, 2026 and a Form 15 on or about March 2, 2026 to terminate its Section 12(g) registration and suspend reporting under Sections 13(a) and 15(d) (i.e., “going dark”).

Key Details

• Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 in stockholders’ equity; SSKN was found non‑compliant.
• Nasdaq accepted SSKN’s plan on October 13, 2025 and granted an extension to February 16, 2026.
• SSKN engaged two investment banks, confidentially submitted an S-1 for an equity offering, and held dozens of investor meetings but did not secure sufficient funding.
• Company notified Nasdaq on Feb 9, 2026 it could not meet the extension; Nasdaq notified SSKN on Feb 10, 2026 that trading will be suspended at market open on Feb 19, 2026 and a Form 25-NSE will be filed; SSKN will not appeal.

Why It Matters
Delisting and deregistration mean SSKN’s shares will be removed from Nasdaq and the company will stop regular SEC reporting, significantly reducing public disclosure and likely making the stock harder to buy or sell (lower liquidity). The company says the move will cut administrative costs and allow management to focus on operations and reducing cash burn, which it views as beneficial for long‑term value. For shareholders, the key immediate impact is reduced market liquidity; holders who want to sell may be able to do so before the Feb 19, 2026 trading suspension.